WASHINGTON, Feb. 12, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2012.
FULL YEAR 2012 REPORTED RESULTSTotal revenues for the full year 2012 were $32.7 million, compared to $31.3 million for 2011. Full year 2012 revenues included $5.9 million in Fanapt® royalties received from Novartis, as compared to $4.5 million for the prior year. Both 2012 and 2011 revenues include $26.8 million recognized from the $200.0 million upfront payment previously received from Novartis for Fanapt® U.S. and Canadian rights.
Total operating expenses for 2012 were $61.0 million, compared to $42.0 million for 2011. The primary driver of the higher expenses in 2012 was the ongoing support of the tasimelteon Non-24 and MDD clinical studies.
Vanda recorded a net loss of $27.7 million for 2012, compared to net loss of $9.8 million for 2011. Diluted net loss per share for 2012 was $0.98, compared to a diluted net loss per share of $0.35 for 2011.
Vanda's cash, cash equivalents and marketable securities as of December 31, 2012 totaled $120.4 million.
FOURTH QUARTER 2012 REPORTED RESULTSTotal revenues for the fourth quarter of 2012 were $7.9 million, compared to $8.4 million for 2011. Fourth quarter 2012 revenues included $1.2 million in Fanapt® royalties received from Novartis as compared to royalties of $1.6 million for the fourth quarter of 2011.Total operating expenses for the fourth quarter of 2012 and 2011 were each $14.3 million.
Vanda recorded a net loss of $6.4 million for the fourth quarter of 2012, compared to a net loss of $5.5 million for the fourth quarter of 2011. Diluted net loss per share for the fourth quarter of 2012 was $0.23, compared to a diluted net loss of $0.20 per share for the fourth quarter of 2011.
Full Year December 31, 2012 Key Financial Figures1
Twelve Months EndedDecember 31December 31(in thousands, except per share amounts)20122011 Change ($)Change (%)Total revenues
,4575%Research & development expenses
45,44628,99616,45057%General & administrative expenses
13,88211,4862,39621%Non-cash stock-based compensation2
4,0945,501(1,407)(26%)Loss before tax benefit
(27,664)(9,802)(17,862)(182%)Diluted net loss per share
(0.63)(180%) Fourth Quarter 2012 Key Financial Figures1Three Months EndedDecember 31September 30(in thousands, except per share amounts)20122012 Change ($)Change (%)Total revenues
(368)(4%)Research & development expenses
10,61710,1594585%General & administrative expenses
3,2253,147782%Non-cash stock-based compensation2
92357634760%Loss before tax benefit
(6,369)(5,326)(1,043)(20%)Diluted net loss per share
(0.04)(21%) Select Cash Flow Data1 Twelve Months EndedDecember 31December 31(in thousands)20122011Net cash provided by (used in)Operating activities
1225 Select Balance Sheet Data1 December 31September 30December 31(in thousands)201220122011Total cash and marketable securities
7,896(1) Unaudited(2) Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses OPERATIONAL HIGHLIGHTSIn December 2012 and January 2013, Vanda announced positive results for two Phase III studies for tasimelteon in the treatment of Non-24. The SET Phase III study demonstrated that tasimelteon was able to entrain the master body clock as measured by melatonin and cortisol circadian rhythms. Tasimelteon was also shown to significantly improve clinical symptoms across a number of sleep and wake measures. These results provided robust evidence of direct and clinically meaningful benefits to patients with Non-24. The RESET Phase III study demonstrated the maintenance effect of 20mg of tasimelteon to entrain melatonin and cortisol circadian rhythms in individuals with Non-24.
Patients treated with tasimelteon maintained their clinical benefits while patients receiving placebo showed significant deterioration in measures of nighttime sleep, daytime naps and timing of sleep. Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals who lack light perception and cannot entrain (reset) their master body clock to the 24-hour day. Currently there is no approved treatment for Non-24.
Vanda plans to submit an NDA to the FDA in mid-2013. Vanda will meet with the FDA in Q1 of 2013 for a pre-NDA meeting on tasimelteon in the treatment of patients with Non-24.
Vanda has decided to discontinue all activities related to the MDD indication. In January, Vanda announced that the MAGELLAN Phase IIb/III clinical study in MDD did not meet the primary endpoint of a change from baseline in the Hamilton Depression Scale (HAMD-17) after 8 weeks of treatment as compared to placebo.
Vanda has formally appealed the EMA's negative opinion for Fanaptum™ (oral iloperidone tablets) and requested a re-examination of the decision by the EMA's Committee for Medicinal Product for Human Use (CHMP). In December 2012, the CHMP issued a negative opinion recommending against approval of Fanaptum™ for the treatment of schizophrenia in adult patients in the European Union.Vanda recorded full year 2012 revenue of $32.7 million including Fanapt® royalties of $5.9 million. Fanapt® prescriptions, as reported by IMS, were approximately 38,200 for the fourth quarter of 2012. This represents a 1% decrease versus third quarter 2012 prescriptions and a 13% increase over fourth quarter 2011 prescriptions.CONFERENCE CALLVanda has scheduled a conference call for today, Tuesday, February 12, 2013, at 10:00 AM ET. During the call, Vanda's management will discuss the fourth quarter and full year 2012 results and other corporate activities. Investors can call 800-901-5248 (domestic) and 617-786-4512 (international) and use passcode 86594010. A replay of the call will be available beginning Tuesday, February 12, 2013 at 12:00 PM ET and will be accessible until Tuesday, February 19, 2013, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 89804635.
The conference call will be broadcast simultaneously on Vanda's website, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda's website for a period of 30 days, through March 14, 2013.
ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSVarious statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the inability to reach agreement with the FDA regarding Vanda's regulatory approval strategy or proposed path to approval for tasimelteon for the treatment of Non-24; Vanda's failure to obtain regulatory approval for tasimelteon for the treatment of Non-24 or to comply with ongoing regulatory requirements; the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda's ability to successfully commercialize Fanapt® outside of the U.S. and Canada and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2011 which is on file with the SEC and available on the SEC's website at www.sec.gov. In addition to the risks described above and in Vanda's annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other filings with the SEC, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. VANDA PHARMACEUTICALS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)Three Months EndedTwelve Months Ended(in thousands, except for share)
December 31December 31December 31December 31and per share amounts)2012201120122011Revenues:Licensing agreement$
26,789Royalty revenue1,1681,6185,9384,481Total revenues7,9208,37032,72731,270Operating expenses:Cost of sales129-129-Research and development10,61710,55645,44628,996General and administrative3,2253,34513,88211,486Intangible asset amortization3773771,4951,495Total operating expenses14,34814,27860,95241,977Loss from operations(6,428)(5,908)(28,225)(10,707)Other income5999561461Loss before tax benefit(6,369)(5,809)(27,664)(10,246)Tax benefit-(286)-(444)Net loss$
(9,802)Net loss per share:Basic$
(0.35)Shares used in calculation of net lossper share:Basic 28,233,40928,115,17528,228,40928,106,831Diluted28,233,40928,115,17528,228,40928,106,831VANDA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(in thousands)December 31, 2012December 31, 2011ASSETSCurrent assets:Cash and cash equivalents$
87,923Marketable securities, current31,63160,961Accounts receivable1,1681,618Inventory57-Prepaid expenses and other current assets3,9102,999Restricted cash, current430-Total current assets125,968153,501Marketable securities, non-current-19,012Property and equipment, net2,348964Other assets, non-current-84Intangible asset, net6,5328,027Restricted cash, non-current6001,030Total assets$
182,618LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$
996Accrued liabilities5,1873,381Deferred rent, current-453Deferred revenues, current26,78926,789Total current liabilities32,26331,619Non-current liabilities:Deferred rent, non-current3,005461Deferred revenues, non-current90,275117,064Total liabilities125,543149,144Stockholders' equity:Common stock2828Additional paid-in capital300,974296,868Accumulated other comprehensive income1021Accumulated deficit(291,107)(263,443)Total stockholders' equity9,90533,474Total liabilities and stockholders' equity$
Senior Communications Manager
Vanda Pharmaceuticals Inc.
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2012 PR Newswire.
All rights reserved